Accuray (ARAY) Stock
Precision radiation therapy systems and services for hospitals. Here's the price, business snapshot, and what's worth knowing about Accuray in August 2026.
Accuray Incorporated (ARAY) designs and sells precision radiation therapy systems used to treat cancer, including the CyberKnife and Radixact platforms. The company supplies hardware, software and ongoing services to hospitals and cancer centres worldwide. With a modest market capitalisation of about $181.48M, Accuray is a small-cap medical‑devices business where revenue can be driven by equipment sales, upgrade cycles and recurring service or software contracts. Investors should note the typical industry dynamics: long capital outlays by customers, regulatory oversight, and competition from larger vendors. That combination can create periodic volatility in sales and margins. Accuray’s prospects hinge on product adoption, technological differentiation and stable service revenues, but there are execution and market‑share risks. This summary is educational only and not investment advice; individual suitability depends on your goals, timeframe and risk tolerance. Past performance is not a reliable indicator of future results and values can fall as well as rise.
About This Stock
ACCURAY INCORPORATED
ARAY
Current Price
$0.30
Potential 12 Month Profit
1,737.74%
Sector
Healthcare
Industry
Healthcare Equipment & Supplies
Ticker
ARAY
Market Cap
$35.21M
Potential 12 Month Profit
1,737.74%
Sector
Healthcare
Industry
Healthcare Equipment & Supplies
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Accuray's stock, expecting it to rise significantly in value.
Financial Health
Accuray is generating steady cash flow and revenue, but its profitability margins are modest.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Adoption and upgrades
Equipment sales and upgrade cycles can drive revenue spikes, though buying decisions by hospitals are often lengthy and cyclical.
Technology edge
Differentiation via accuracy, software and workflow matters for market share, but competitors and regulatory hurdles can slow uptake.
Service revenues matter
Recurring service and software contracts can stabilise cash flow, yet overall performance will still vary and is not guaranteed.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.